Filing Flows › 8-K events › Supernus Pharmaceuticals
Supernus Pharmaceuticals: termination of a material definitive agreement
Form 8-K filed Oct 26, 2026 · items 1.02
What the filing says
On October 20, 2026, Supernus Pharmaceuticals, Inc. (the “Company”) terminated the UBS Credit Line Agreement, dated as of February 8, 2023 (the “UBS Credit Line”), between the Company and UBS Bank USA (the “Bank”), which established an uncommitted, demand revolving line of credit. The Company terminated the UBS Credit
Read the filing on SEC EDGAR →
What usually followsAcross 2,368 8-Ks reporting Item 1.02 (termination of a material agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.5%, up 51% of the time); over the following 21 sessions, +1.1%. Every item ranked →
What this kind of filing means
Item 1.02 — Termination of a material definitive agreement. Ending a material agreement can remove revenue, financing or a planned deal; the filing says who ended it and whether penalties apply.
Supernus Pharmaceuticals at a glance
Supernus Pharmaceuticals, Q3 2026: revenue $227M (+18% year over year), operating margin 9.3%. The chart follows the revenue to costs, profit and cash.
Supernus Pharmaceuticals: every quarter, Q/Q and Y/Y, holders and guidance →
Supernus Pharmaceuticals’s other material 8-Ks
- Nov 2, 2026 — Delisting notices
- Nov 2, 2026 — Changes in control Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader
- Oct 22, 2026 — FDA decisions Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl)
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.